• 1. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 2. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 3. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Aminopyrimidines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Aminopyrimidines and derivatives

Research Brief on N1-(4-Methylpyrimidin-2-yl)ethane-1,2-diamine (CAS: 761339-87-1): Recent Advances and Applications

N1-(4-Methylpyrimidin-2-yl)ethane-1,2-diamine (CAS: 761339-87-1) is a structurally unique compound that has garnered significant attention in the field of chemical biology and medicinal chemistry. Recent studies have explored its potential as a key intermediate in the synthesis of novel therapeutic agents, particularly in the development of kinase inhibitors and antimicrobial compounds. This research brief aims to summarize the latest findings related to this compound, highlighting its synthetic pathways, biological activities, and potential applications in drug discovery.

One of the most notable advancements in the study of N1-(4-Methylpyrimidin-2-yl)ethane-1,2-diamine is its role in the synthesis of pyrimidine-based kinase inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory activity against cyclin-dependent kinases (CDKs), which are critical targets in cancer therapy. The researchers utilized a structure-activity relationship (SAR) approach to optimize the compound's binding affinity, resulting in derivatives with nanomolar potency against CDK2 and CDK4.

In addition to its applications in oncology, N1-(4-Methylpyrimidin-2-yl)ethane-1,2-diamine has shown promise in antimicrobial research. A recent preprint on BioRxiv reported that this compound serves as a scaffold for the development of novel antibiotics targeting multidrug-resistant Gram-negative bacteria. The study highlighted its ability to disrupt bacterial cell wall synthesis by inhibiting key enzymes involved in peptidoglycan biosynthesis. These findings underscore the compound's versatility and potential to address pressing global health challenges.

The synthetic accessibility of N1-(4-Methylpyrimidin-2-yl)ethane-1,2-diamine has also been a focal point of recent research. A 2022 paper in Organic Letters detailed an efficient, one-pot synthesis method that significantly improves yield and reduces production costs. This methodological advancement is expected to facilitate broader adoption of the compound in both academic and industrial settings, enabling more extensive exploration of its pharmacological properties.

Despite these promising developments, challenges remain in the clinical translation of N1-(4-Methylpyrimidin-2-yl)ethane-1,2-diamine-based therapeutics. Pharmacokinetic studies indicate that further optimization is needed to enhance bioavailability and reduce off-target effects. Ongoing research is investigating prodrug strategies and formulation technologies to overcome these limitations, with preliminary results showing improved plasma stability in animal models.

In conclusion, N1-(4-Methylpyrimidin-2-yl)ethane-1,2-diamine (CAS: 761339-87-1) represents a valuable chemical entity with diverse applications in drug discovery. Its role in kinase inhibition and antimicrobial activity, coupled with recent synthetic advancements, positions it as a compound of significant interest for future therapeutic development. Continued research efforts will be crucial to fully realize its potential in addressing unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)